Results 81 to 90 of about 120,218 (287)
Synergy between chemotherapeutic agents and CTLA-4 blockade in preclinical tumor models [PDF]
, 2013 Ipilimumab, a cytotoxic T-lymphocyte antigen-4 (CTLA-4) binding agent, has proven to be an effective monotherapy for metastatic melanoma and has shown antitumor activity in trials when administered with other therapeutic agents.
Emel Girit +6 more
core +1 more source
Depletion of the RNA‐Editing Enzyme ADAR1 Invigorates the Antitumor Immunity of NK Cells
Advanced Science, EarlyView.ADAR1 is upregulated in NK cells from melanoma patients, impairing their function. Its loss enhances NK cell tumor infiltration and cytotoxicity in vitro and in vivo. Mechanistically, ADAR1 deficiency destabilizes CD38 mRNA to reduce its expression, thereby increasing NK cell mobility and killing, which nominates it as a therapeutic target for NK cell ...
Shuhan Chen +11 more
wiley +1 more source
Benefiting from CTLA-4 blockade—a genetic rationale [PDF]
, 2014 Alessia Errico
openalex +1 more source
Immune targets in the tumor microenvironment treated by radiotherapy. [PDF]
, 2019 Radiotherapy (RT), the major anti-cancer modality for more than half of cancer patients after diagnosis, has the advantage of local tumor control with relatively less systematic side effects comparing to chemotherapy.
Li, Jian Jian +2 more
core
Early Investigations and Recent Advances in Intraperitoneal Immunotherapy for Peritoneal Metastasis. [PDF]
, 2018 Peritoneal metastasis (PM) is an advanced stage malignancy largely refractory to modern therapy. Intraperitoneal (IP) immunotherapy offers a novel approach for the control of regional disease of the peritoneal cavity by breaking immune tolerance.
Bowne, Wilbur B. +5 more
core +2 more sources
Advanced Science, EarlyView.This study identifies TOPK as a dual‐function target in gastric cancer: it drives tumor cell proliferation and migration, and under IFN‐γ stimulation, phosphorylates eIF4F complex component eIF4A1 to enhance STAT1 mRNA translation, thereby promoting PD‐L1/IDO1‐mediated tumor immunometabolic evasion.
Junbing Chen +16 more
wiley +1 more source
Advanced Science, EarlyView.A multifunctional mPDZM nanoplatform is developed in this study. mPDZM integrates chemotherapy‐induced senescence, selective senolysis, and STING‐mediated immune activation. mPDZM effectively clears senescent tumor cells, remodels the tumor immune microenvironment, and enhances antitumor T‐cell responses.
Shiji Fang +17 more
wiley +1 more source
Advanced Science, EarlyView.Cytokine‐engineered CAR‐T cells represent a promising immunotherapy against malignancies due to direct tumor killing and potent immunity response. However, significant toxicities, including CRS and ICANS, have restricted clinical applications. How to keep the risk‐benefit balance of the advanced therapy is of great importance for maximizing the benefit
Xinru Zhang +7 more
wiley +1 more source
Trojan Horse Strategy: How Biomimetic Nanomedicine Remodels the Tumor Microenvironment
Advanced Science, EarlyView.This review focuses on biomimetic nanomedicines for tumor microenvironment (TME) remodeling, covering their diverse biomimetic types, design principles, and mechanisms of immune cell reprogramming and reversal of immunosuppressive microenvironments, with particular emphasis on their application in synergistic immunotherapy.
Wanrong Wang +7 more
wiley +1 more source
Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8+ T cells directly within the tumor microenvironment [PDF]
, 2014 Stefani Spranger +5 more
openalex +1 more source